Chennai: VCK chief Thol Thirumavalavan has said he won't be able to share the stage with actor and TVK leader Vijay at an Ambedkar book release event in Chennai on Dec 6, citing the current political situation. The DMK camp had conveyed its unhappiness about a senior ally planning to share dais with Vijay, especially after the actor took on DMK (without mentioning it by name) at TVK's Vikravandi conference last month. A representative of the media house which is organising the event said, "Thirumavalavan has conveyed his inability to attend the event." Ellorukkumana Thalaivar Ambedkar' a compilation of articles featuring dalit icon B R Ambedkar's work, including an interview with Thirumavalavan himself, will be released on the occasion. Maharashtra Jharkhand Maharashtra Alliance View i Party View Seats: 288 Results Majority: 145 BJP+ 229 MVA 47 OTH 12 Results : 288 / 288 BJP+ WON Jharkhand Alliance View i Party View Seats: 81 Results Majority: 41 INDIA 56 NDA 24 OTH 1 Results : 81 / 81 INDIA WON Source: PValue VCK sources said Thirumavalavan communicated his inability to participate, pointing to the political ramifications, particularly after Vijay's statements and strident criticism of DMK's "Dravida model govt" at the TVK conference. "The VCK leader even proposed alternative arrangements, suggesting separate events in Chennai and Madurai for himself and the actor," a source said. Sources told TOI that DMK "well-wishers", concerned about the optics of VCK sharing a platform with a political opponent, advised Thirumavalavan against attending it. This advice also follows Thirumavalavan appearing with chief minister M K Stalin at a govt event in his constituency. Stalin even praised the VCK leader in an epistle to the partymen, saying, "I know the mind of my dear brother Thirumavalavan. He also shows true affection to me as an elder brother. He is aware of my resolute actions." A section of VCK is unhappy with the media house's decision to prioritize Vijay over Thirumavalavan for the Ambedkar book release. "Thirumavalavan is a staunch advocate of Ambedkar ideology, while secular credentials of Vijay are yet to be proven," VCK MP D Ravikumar said. Thirumavalavan, along with INDIA bloc partners, is expected to take part in DMK's third national conference of All India Federation for Social Justice in Delhi on Dec 3.
Thanksgiving Travel Latest: Airport strike, staff shortages and weather could impact holiday travelJapan's First Memorial At Sado Gold Mines Sparks WWII Controversy
Vishay Intertechnology, Inc VSH stock gained after analyst Ming-Chi Kuo commented on the stock on social media. While the tech industry focuses on NVIDIA Corp’s NVDA AI server and RTX 50 series supply chain, Kuo’s research reveals Vishay as the hidden key winner. According to the analyst, Vishay has secured better-than-expected orders for Nvidia’s Blackwell AI servers (GB200 series and DGX/HGX B200) and RTX 50 series graphics cards. Also Read: Meta, OpenAI, Orange Join Forces To Build AI Models For African Languages The component orders include MOSFET/DrMOS (VRPower), vPolyTan (Polymer Tantalum, such as T55) and Current Shunt Resistors. Kuo said MOSFET and vPolyTan deserve special attention. He noted that for GB200 NVL72/36’s 8kW 54V-to-12V power supply, Nvidia switched to a Renesas (controller) and Vishay (MOSFET) combination, replacing power management modules from Flextronics and Delta. Notably, Vishay replaced Infineon as the current MOSFET supplier. For DGX/HGX’s 2kW 54V-to-12V power supply, Nvidia now uses ADI (controller) and Vishay (MOSFET), Kuo flagged. The GB200 NVLink Switch’s 2kW 54V-to-12V power supply also uses the Renesas (controller) and Vishay (MOSFET) combination. The analyst noted that Vishay became the new DrMOS supplier for Nvidia’s upcoming RTX 50 series graphics cards. Mass production will start in the first quarter of 2025. Vishay’s current MOSFET production capacity in 2025 is fully loaded, and it will likely contribute 20%–30% of revenue, with a higher-than-average gross profit margin, as per the analyst. GB200 heavily utilizes Vishay’s vPolyTan (polymer tantalum capacitors, primarily T55). Vishay’s vPolyTan is already facing a supply crunch for 2025 and will likely contribute a high single-digit percentage of revenue with significantly above-average gross margins. Vishay has the potential to capitalize on robust demand for Nvidia’s AI servers and the new RTX 50 series. He noted the company is also well-positioned to benefit from the automotive sector’s rebound and the IoT market. Price Actions: VSH stock is up 7.12% at $18.35 at last check Tuesday. NVDA is up 0.51% at $136.75. Also Read: Microsoft Service Disruption Hits Outlook And Teams, Thousands Report Issues Photo: Shutterstock © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.NEW YORK (AP) — Shohei Ohtani wins his third MVP and first in the NL following a historic offensive season with the Los Angeles Dodgers.
Maharashtra's politics: For Sharad Pawar, results raise questions about futureInvestors with a lot of money to spend have taken a bearish stance on Riot Platforms RIOT . And retail traders should know. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with RIOT, it often means somebody knows something is about to happen. So how do we know what these investors just did? Today, Benzinga 's options scanner spotted 9 uncommon options trades for Riot Platforms. This isn't normal. The overall sentiment of these big-money traders is split between 44% bullish and 55%, bearish. Out of all of the special options we uncovered, 2 are puts, for a total amount of $108,053, and 7 are calls, for a total amount of $247,558. What's The Price Target? Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $11.5 to $25.0 for Riot Platforms during the past quarter. Insights into Volume & Open Interest Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Riot Platforms's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Riot Platforms's substantial trades, within a strike price spectrum from $11.5 to $25.0 over the preceding 30 days. Riot Platforms 30-Day Option Volume & Interest Snapshot Noteworthy Options Activity: Symbol PUT/CALL Trade Type Sentiment Exp. Date Ask Bid Price Strike Price Total Trade Price Open Interest Volume RIOT PUT SWEEP BULLISH 12/06/24 $1.13 $1.12 $1.13 $12.00 $71.3K 899 810 RIOT CALL SWEEP BEARISH 12/20/24 $0.6 $0.59 $0.59 $15.00 $48.3K 14.4K 517 RIOT CALL TRADE BULLISH 03/21/25 $2.1 $2.02 $2.08 $15.00 $41.6K 38.4K 473 RIOT CALL TRADE BULLISH 01/16/26 $3.2 $3.1 $3.2 $22.00 $38.4K 2.7K 123 RIOT PUT TRADE BEARISH 01/03/25 $1.47 $1.47 $1.47 $11.50 $36.7K 8 251 About Riot Platforms Riot Platforms Inc is a vertically integrated Bitcoin mining company focused on building, supporting, and operating blockchain technologies. The company's segments include Bitcoin Mining; Data Center Hosting and Engineering. It generates maximum revenue from the Bitcoin Mining segment which generates revenue from the Bitcoin the company earns through its mining activities. Having examined the options trading patterns of Riot Platforms, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance Current Position of Riot Platforms Trading volume stands at 16,034,233, with RIOT's price down by -5.14%, positioned at $11.44. RSI indicators show the stock to be may be approaching overbought. Earnings announcement expected in 86 days. What Analysts Are Saying About Riot Platforms In the last month, 4 experts released ratings on this stock with an average target price of $14.625. Unusual Options Activity Detected: Smart Money on the Move Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. Click here for access .* An analyst from Needham downgraded its action to Buy with a price target of $11. * Consistent in their evaluation, an analyst from Compass Point keeps a Buy rating on Riot Platforms with a target price of $13. * An analyst from HC Wainwright & Co. has revised its rating downward to Buy, adjusting the price target to $17. * An analyst from Macquarie has decided to maintain their Outperform rating on Riot Platforms, which currently sits at a price target of $17. Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely. If you want to stay updated on the latest options trades for Riot Platforms, Benzinga Pro gives you real-time options trades alerts. © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
NoneA look at some of the latest stock recommendations by analysts. These stocks are expected to return between 22% and 56% as per analysts’ price targets. Genesys International BROKERAGE: ELARA Price Target: Rs 1,350 CMP: Rs 878 Upside: 56% Initiate with buy; price target refl ects robust potential in the high-growth geospatial segment Positioned to capitalise on India’s projected Rs 293-billion geospatial market by 2030; order book at Rs 3.9 billion Risks include high working capital days, dependency on government projects, and customer concentration Awfis Space Solutions BROKERAGE: IIFL SECURITIES Price Target: Rs 980 CMP: Rs 719 Upside: 36% Initiate with buy; only listed pure play on the flexible workspaces segment Company may turn profi table in FY25; profi t after tax seen doubling on a compounded basis over three years Over FY25-27, seat additions could grow at 30% on a compounded basis, outpacing industry growth estimates at 15% Emcure Pharmaceuticals Stock Trading Renko Chart Patterns Made Easy By - Kaushik Akiwatkar, Derivative Trader and Investor View Program Stock Trading Derivative Analytics Made Easy By - Vivek Bajaj, Co Founder- Stockedge and Elearnmarkets View Program Stock Trading Macroeconomics Made Easy: Online Certification Course By - Anirudh Saraf, Founder- Saraf A & Associates, Chartered Accountant View Program Stock Trading Technical Analysis Demystified: A Complete Guide to Trading By - Kunal Patel, Options Trader, Instructor View Program Stock Trading Options Trading Course For Beginners By - Chetan Panchamia, Options Trader View Program Stock Trading Stock Investing Made Easy: Beginner's Stock Market Investment Course By - elearnmarkets, Financial Education by StockEdge View Program Stock Trading Advanced Strategies in Stock Market Mastery By - CA Raj K Agrawal, Chartered Accountant View Program Stock Trading Heikin Ashi Trading Tactics: Master the Art of Trading By - Dinesh Nagpal, Full Time Trader, Ichimoku & Trading Psychology Expert View Program Stock Trading Stock Valuation Made Easy By - Rounak Gouti, Investment commentary writer, Experience in equity research View Program Stock Trading Options Trading Made Easy: Options Trading Course By - Anirudh Saraf, Founder- Saraf A & Associates, Chartered Accountant View Program Stock Trading Markets 102: Mastering Sentiment Indicators for Swing and Positional Trading By - Rohit Srivastava, Founder- Indiacharts.com View Program Stock Trading Introduction to Technical Analysis & Candlestick Theory By - Dinesh Nagpal, Full Time Trader, Ichimoku & Trading Psychology Expert View Program Stock Trading Technical Trading Made Easy: Online Certification Course By - Souradeep Dey, Equity and Commodity Trader, Trainer View Program Stock Trading Technical Analysis for Everyone - Technical Analysis Course By - Abhijit Paul, Technical Research Head, Fund Manager- ICICI Securities View Program Stock Trading Mastering Options Selling: Advanced Strategies for Success By - CA Manish Singh, Chartered Accountant, Professional Equity and Derivative Trader View Program BROKERAGE: KOTAK INSTITUTIONAL Price Target: Rs 1,680 CMP: Rs 1,374 Upside: 22% Post recent correction, upgrade the stock to 'buy' from 'add' Among a few major Indian pharma players, with no meaningful direct US generics exposure, lending greater earnings stability Improved productivity and higher utilisation of the new facilities to drive robust 29% Earnings Per Share growth on a compounded basis over FY24-27 (You can now subscribe to our ETMarkets WhatsApp channel )Judge rejects request to sideline a San Jose State volleyball player on grounds she’s transgender
COPENHAGEN, Denmark, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the U.S. Food & Drug Administration (FDA) has accepted for review its supplemental Biologics License Application (sBLA) in adult growth hormone deficiency (GHD) for TransCon hGH (lonapegsomatropin-tcgd; marketed as SKYTROFA® for pediatric GHD). The FDA set a Prescription Drug User Fee Act (PDUFA) goal date of July 27, 2025. “This marks another step towards achieving our objective to expand SKYTROFA’s label beyond pediatric GHD and expand its reach to address new groups of patients,” said Jan Mikkelsen, Ascendis Pharma’s President and Chief Executive Officer. “Adult GHD is an undertreated condition associated with significant comorbidities and higher annual healthcare costs compared to the 5-10% of patients who receive treatment, indicative of the high unmet need.” The sBLA submission is based on results from foresiGHt, a Phase 3 randomized, parallel-arm, placebo-controlled (double-blind) and active-controlled (open-label) trial that compared the efficacy and safety of weekly TransCon hGH with weekly placebo and daily human growth hormone (hGH) in adults with GHD. The trial evaluated 259 adults with GHD aged 23 to 80 years old, randomized 1:1:1, titrated to receive a target fixed dose of TransCon hGH, placebo, or daily hGH based on age and oral estrogen intake with approximately equivalent hGH mg/week for TransCon hGH and daily hGH. TransCon hGH demonstrated superiority on its primary efficacy and key secondary efficacy endpoints at Week 38, with TransCon hGH-treated participants showing a statistically significant reduction from baseline in trunk fat and increase in total body lean mass at Week 38 compared to placebo. In the trial, TransCon hGH was generally safe and well tolerated, with no discontinuations related to study drug and with comparable safety and tolerability to daily hGH treatment. About Adult Growth Hormone Deficiency Growth hormone plays an essential role in the health of children and adults, promoting normal growth in children and maintenance of normal body composition and cardiometabolic health throughout adulthood. In adults, growth hormone boosts protein production, promotes fat utilization, enhances muscle mass, and helps regulate blood sugar levels. Adult GHD is a condition in which an individual’s body does not produce enough growth hormone. Symptoms and morbidity can include central obesity, metabolic syndrome, decreased bone density, alterations in lipid profile and markers of cardiovascular risk, fatigue, general weakness, lack of muscle tone, and psychological symptoms such as cognitive impairment, social isolation, lack of motivation, and depression.1 About Ascendis Pharma A/S Ascendis Pharma is applying its innovative TransCon technology platform to build a leading, fully integrated biopharma company focused on making a meaningful difference in patients’ lives. Guided by its core values of Patients, Science, and Passion, Ascendis uses its TransCon technologies to create new and potentially best-in-class therapies. Ascendis is headquartered in Copenhagen, Denmark and has additional facilities in Europe and the United States. Please visit ascendispharma.com to learn more. Forward-Looking Statements This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Ascendis’ future operations, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to (i) the PDUFA goal date for SKYTROFA, (ii) Ascendis’ objective to expand SKYTROFA’s label and reach to address new groups of patients, (iii) Ascendis’ ability to apply its TransCon technology platform to build a leading, fully integrated biopharma company, and (iv) Ascendis’ use of its TransCon technologies to create new and potentially best-in-class therapies. Ascendis may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations, and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Ascendis makes, including the following: dependence on third party manufacturers, distributors and service providers for Ascendis’ products and product candidates; unforeseen safety or efficacy results in Ascendis’ development programs or on-market products; unforeseen expenses related to commercialization of any approved Ascendis products; unforeseen expenses related to Ascendis’ development programs; unforeseen selling, general and administrative expenses, other research and development expenses and Ascendis’ business generally; delays in the development of its programs related to manufacturing, regulatory requirements, speed of patient recruitment or other unforeseen delays; Ascendis’ ability to obtain additional funding, if needed, to support its business activities; the impact of international economic, political, legal, compliance, social and business factors. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Ascendis’ business in general, see Ascendis’ prospectus supplement filed on September 20, 2024 and Ascendis’ current and future reports filed with, or submitted to, the U.S. Securities and Exchange Commission (SEC), including its Annual Report on Form 20-F filed with the SEC on February 7, 2024. Forward-looking statements do not reflect the potential impact of any future licensing, collaborations, acquisitions, mergers, dispositions, joint ventures, or investments that Ascendis may enter into or make. Ascendis does not assume any obligation to update any forward-looking statements, except as required by law. Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company logo, TransCon, and SKYTROFA ® , are trademarks owned by the Ascendis Pharma group. © December 2024 Ascendis Pharma A/S. 1.Hoffman AR, Mathison T, Andrews D, Murray K, Kelepouris N, Fleseriu M. Adult Growth Hormone Deficiency: Diagnostic and Treatment Journeys From the Patients' Perspective. J Endocr Soc. 2022;6(7):bvac077. Published 2022 May 12. doi:10.1210/jendso/bvac077
Simon Harris said he has apologised to a woman for not giving her enough time to speak about carers and disability services while he was out canvassing in Cork on Friday. The Taoiseach and Fine Gael leader said he spoke to Charlotte Fallon, a worker with St Joseph’s Foundation, on the phone on Saturday after a clip of an exchange between them on Friday went viral. Advertisement RTÉ footage posted to the social media site X shows Mr Harris on a canvass in Kanturk when Ms Fallon tells the Taoiseach carers “were ignored” and the Government has “done nothing for us”. “The disability sector is a joke,” she says. “You’ve done nothing for us, our people are suffering. I’m very passionate about my job.” Mr Harris responds by saying: “No, not at all,” and: “I’m very passionate about disability too.” Ms Fallon says: “But there’s no mention of (them in the) Budget. You ignored them, you ignore the carers,” to which Mr Harris says: “That’s not true,” several times before shaking her hand and walking away. Advertisement While out canvassing at a Christmas market in Rathfarnham in Dublin on Saturday afternoon, Mr Harris said he was annoyed with himself and had called Ms Fallon to apologise. “I called Charlotte this morning because she was absolutely owed an apology from me,” he said. “We had a very good conversation, a very good conversation. I was very grateful to her for her time and her kindness. Advertisement “We spoke about a number of issues, we spoke about disability services, we spoke about the issue of pay parity for people in Section 39 organisations, and we also spoke about the issue of the means test for carers. “I was grateful to have a chance to listen to Charlotte and also talk through with her some of my own plans and views and vision in relation to disability services. Really grateful for the conversation, learned a lot from it, and I’ve also said that I’d love to call in to where she works in Cork in the coming weeks, and she said I’d be very welcome. “I’m annoyed with how I didn’t give that person, Charlotte, the time last night, she deserved that time. Advertisement Mr Harris said he had called to apologise over the encounter (Fine Gael/PA) “I’ve been around the country and I’ve had hundreds of conversations some days, and I’ve learned a lot and always learned a lot from listening to people and I’m very sorry that didn’t happen last night.” Asked what happened last night, he said: “There’s no excuse for it, I’m annoyed with myself in relation to it, disability is what makes me tick. “It will always be my passion, and it’s Charlotte’s passion too, and I’m really grateful to her for giving me the opportunity to speak with her today.” Advertisement Asked whether he thought people would doubt his sincerity on wanting to reform the State’s disability services after seeing the video, Mr Harris said: “I hope not. “All I can do is really double my efforts to convince people of the facts that we have a plan for the future of this country, and very much at the heart of that plan is better services, better delivery and better empowerment of people with disabilities. “I’ve tried to bring a focus to it since I’ve become Taoiseach, and it’s something that I will continue to work on intensively and even more intensively as a result of this.” On Saturday morning, Mr Harris posted a video on Instagram where he said he was spurred on to become a politician after seeing his parents fight for access to services for his brother Adam, who has autism. He said the interaction happened at the end of a “very long day” and he felt “really bad” about it. Mr Harris said the encounter had come at the end of a long day (Grainne Ni Aodha/PA) Mr Harris then outlined his party’s plans for carers and the disability sector, including removing the means testing for the Carers’ Allowance and to ensure that there are therapies in special schools and special classes. Sinn Féin’s housing spokesperson Eoin Ó Broin said that Mr Harris’ reaction “showed the true face of Fine Gael” and showed “a contempt for working people”. Speaking at a press event in Dublin on Saturday, Fine Gael ministers Helen McEntee and Paschal Donohoe defended their party leader. Ireland Taoiseach praises Nikita Hand after win in civil c... Read More “I think the Taoiseach himself has been very clear that he wished the encounter had gone differently. It had been the end of a very, very long day,” Ms McEntee said. “What he said very clearly is that he should have given her more time, and should have engaged for longer with her, but this is the reason he got into politics.” Mr Donohoe said: “In the course of an election campaign, in all the interactions that we have with people, of course, we sometimes feel within ourselves ‘that could have gone differently’ and ‘could have gone better’. I think it’s particularly the case for somebody who is so committed to looking at how we can support those who need more.”
Gov. Tim Walz says he’ll propose anti-fraud measures, reflects on VP bidThe AP Top 25 college football poll is back every week throughout the season! Get the poll delivered straight to your inbox with AP Top 25 Poll Alerts. Sign up here . SMITHFIELD, R.I. (AP) — Malik Grant rushed for 204 yards and three touchdowns and Rhode Island beat Bryant 35-21 on Saturday to capture a share of its first league title in 39 years. Rhode Island (10-2, 7-1 Coastal Athletic Association) secured the program’s seventh title, with each of the previous six coming in the Yankee Conference. Rhode Island and Richmond are tied, with the Spiders earning a spot in the FCS playoffs as the CAA’s No. 1 team. Hunter Helms threw for 209 yards with one touchdown and one interception for Rhode Island. Grant also added his first touchdown reception of the season. Grant rushed for 47 yards on the first snap of the second half. He ran for 56 yards on the drive that ended with his 4-yard touchdown catch for a 20-14 lead. An interception by Braden Price on the ensuing Bryant possession set up another Grant rushing touchdown. Bryant scored in the fourth quarter to make it a one-score game, but a 15-play, 72-yard drive ended with a 3-yard touchdown run by Grant. Grant’s 13 rushing touchdowns are tied for Rhode Island’s single-season record set last season by Ja’Den McKenzie. RELATED COVERAGE Auburn wins 43-41, four-OT thriller over playoff hopeful No. 15 Texas A&M Arnold, Robinson run for more than 100 yards as Oklahoma stuns No. 7 Alabama 24-3 No. 22 Iowa State keeps Big 12 title, CFP hopes alive with 31-28 win over Utah Brennan Myer threw for 189 yards with two touchdowns and two interceptions for Bryant (2-10, 0-8). Dylan Kedzior rushed for 80 yards and a touchdown, and Landon Ruggieri caught eight passes for 105 yards and a score. The Rams tied a program record for total wins in a season with 10, first set in 1984 and matched in 1985. ___ Get poll alerts and updates on the AP Top 25 throughout the season. Sign up here . AP college football: https://apnews.com/hub/ap-top-25-college-football-poll and https://apnews.com/hub/college-football